News und Analysen
![Aurinia Closes US$200 Million Public Offering of Common Shares](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Aurinia Closes US$200 Million Public Offering of Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
![Health Canada Approves Cannabis Research License for EnWave’s Canadian Headquarters](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Health Canada Approves Cannabis Research License for EnWave’s Canadian Headquarters
Vancouver, B.C., July 27, 2020 – EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ), announced today
![Health Canada genehmigt Cannabis-Forschungslizenz für das kanadische Hauptquartier von EnWave](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Health Canada genehmigt Cannabis-Forschungslizenz für das kanadische Hauptquartier von EnWave
Vancouver, B.C., 27. Juli 2020 – Die EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) gab
![Puma Biotechnology Announces Publication of Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Puma Biotechnology Announces Publication of Results from Phase II SUMMIT Trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that data from the cervical cancer cohort of SUMMIT, an ongoing Phase II basket trial examining the safety and
![Antibe Therapeutics Reports 2020 Year-End Financial and Operating Results](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Antibe Therapeutics Reports 2020 Year-End Financial and Operating Results
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, July 24 for the fourth quarter and the year ended March 31, 2020
![Arbutus Biopharma: Moderna unter Zugzwang!](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Arbutus Biopharma: Moderna unter Zugzwang!
Bereits vor wenigen Wochen, Mitte und Ende Mai, schrieb ich hier auf sharedeals.de zwei Artikel über Arbutus Biopharma (WKN: A14XMD), Du findest sie hier und hier. Leider setzte die Aktie danach
![Lysogene: First Half 2020 Business Update](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Lysogene: First Half 2020 Business Update
Lysogene (Paris:LYS)(FR0013233475 – LYS), a Phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, provides H1 2020 Business update.
As of 30 June 2020, cash and
![Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 6, 2020, following the release of its second
![Premier Inc. Recommends FDA, DEA Reforms to Prevent Drug Shortages](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Premier Inc. Recommends FDA, DEA Reforms to Prevent Drug Shortages
Premier Inc. (NASDAQ: PINC) today provided the U.S. Food and Drug Administration (FDA) and the U.S. Drug Enforcement Administration (DEA) with a list of reforms and regulatory waivers that the
![Lantheus Holdings to Host Second Quarter 2020 Earnings Conference Call on July 30, 2020 at 8:00 a.m. Eastern Time](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Lantheus Holdings to Host Second Quarter 2020 Earnings Conference Call on July 30, 2020 at 8:00 a.m. Eastern Time
Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call at 8:00 a.m. ET on Thursday, July 30, 2020, to discuss its financial and operating results
![Clovis Oncology to Announce Second Quarter 2020 Financial Results and Host Webcast Conference Call on August 6](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Clovis Oncology to Announce Second Quarter 2020 Financial Results and Host Webcast Conference Call on August 6
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2020 financial results on Thursday, August 6, 2020, after the close of the U.S. financial markets. Clovis’ senior management
![Bayer AG Standardizes on Veeva Vault Clinical Applications Globally](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Bayer AG Standardizes on Veeva Vault Clinical Applications Globally
Veeva Systems (NYSE:VEEV) today announced that Bayer AG (ETR:BAYN) has selected Veeva Vault Study Startup and Veeva Vault eTMF globally to accelerate site activation and improve visibility across
![Aurinia Prices US$200 Million Public Offering of Common Shares](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Aurinia Prices US$200 Million Public Offering of Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
![Aurinia Announces Public Offering of Common Shares](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Aurinia Announces Public Offering of Common Shares
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today
![Global Survey Reveals Urgency to Accelerate Study Start-up](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Global Survey Reveals Urgency to Accelerate Study Start-up
Accelerating study start-up is a top priority for life sciences companies according to the Veeva 2020 Study Start-up Pulse Report & Assessing Post-COVID Readiness, a global study start-up survey of
![Transgene Reports Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-Positive Cancers](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Transgene Reports Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-Positive Cancers
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, performed a pooled analysis of the data
![First Patient Enrolled in Novocure’s EF-33 Phase 2 Pilot Trial of Tumor Treating Fields Delivered Utilizing High-Intensity Transducer Arrays](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
First Patient Enrolled in Novocure’s EF-33 Phase 2 Pilot Trial of Tumor Treating Fields Delivered Utilizing High-Intensity Transducer Arrays
Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in its EF-33 phase 2 pilot trial of Tumor Treating Fields delivered utilizing high-intensity arrays in patients with
![Pfizer and BioNTech Announce an Agreement with U.S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Pfizer and BioNTech Announce an Agreement with U.S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the
![Veeva Extends Remote Meeting Capabilities to Zoom and Microsoft Teams](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Veeva Extends Remote Meeting Capabilities to Zoom and Microsoft Teams
Veeva Systems (NYSE: VEEV) today announced it is bringing Veeva CRM Engage Meeting functionality to Zoom and Microsoft Teams. Now customers will have greater flexibility and choice in how they
![Syneos Health Strengthens Commercial Services with Veeva Commercial Cloud](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Syneos Health Strengthens Commercial Services with Veeva Commercial Cloud
Veeva Systems (NYSE: VEEV) today announced that Syneos Health (NASDAQ: SYNH), one of the industry’s largest providers of outsourced field teams, is offering biopharmaceutical customers Veeva
![STAAR Surgical to Report Second Quarter Results on August 5, 2020](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
STAAR Surgical to Report Second Quarter Results on August 5, 2020
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release
![QIAGEN announces publication of Supplemental Reasoned Position Statement for proposed acquisition by Thermo Fisher](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
QIAGEN announces publication of Supplemental Reasoned Position Statement for proposed acquisition by Thermo Fisher
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the publication of its Supplemental Reasoned Position Statement in response to the amended Offer Document published by Thermo
![QIAGEN gibt Veröffentlichung einer ergänzenden begründeten Stellungnahme zum Übernahmeangebot von Thermo Fisher bekannt](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
QIAGEN gibt Veröffentlichung einer ergänzenden begründeten Stellungnahme zum Übernahmeangebot von Thermo Fisher bekannt
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Veröffentlichung einer ergänzenden begründeten Stellungnahme in Reaktion auf die von Thermo Fisher Scientific Inc (NYSE: TMO)